Most of these deaths occur in patients initially diagnosed with HR+ breast cancer who succumb to their disease after multiple iterations of endocrine therapies plus adjuvants such as CDK4/6 inhibitors or chemotherapy. This evidence concerns the gene CDK4 and breast cancer.